Regeneron Pharmaceuticals REGN Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.97B-4.9% | $3.12B+24.3% | $2.51B+24.7% | $2.02B-34.8% | $3.09B+24.3% | ||
| $5.79B+5.5% | $5.49B-7.6% | $5.94B+8.5% | $5.47B+4.1% | $5.26B-19.4% | ||
| —— | —— | —— | —— | —— | ||
| $5.73B-0.2% | $5.74B+0.9% | $5.69B+1.4% | $5.61B+0.9% | $5.56B-10.5% | ||
| $3.1B-3.0% | $3.2B-1.6% | $3.25B+1.5% | $3.21B+0.4% | $3.19B+3.4% | ||
| $630.7M-1.7% | $641.5M-9.6% | $710M-5.6% | $752.3M-10.3% | $838.5M-4.7% | ||
| $1.52B-7.1% | $1.64B+4.8% | $1.57B+1.4% | $1.54B+5.1% | $1.47B+9.5% | ||
| $620.9M+30.8% | $474.8M-20.3% | $595.6M+3.7% | $574.3M+22.5% | $468.9M+34.3% | ||
| $18.21B+1.0% | $18.02B+0.2% | $17.98B+6.7% | $16.86B-4.1% | $17.57B-5.8% | ||
| $40.87B+0.8% | $40.56B+1.0% | $40.17B+5.1% | $38.22B+1.8% | $37.55B-0.6% | ||
| $1.03B+9.4% | $939M+3.9% | $903.8M+24.9% | $723.9M+2.6% | $705.5M-10.6% | ||
| $636.2M+15.0% | $553M+1.4% | $545.6M+13.2% | $481.9M-22.2% | $619.3M-1.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $5.11B+16.9% | $4.37B-1.3% | $4.43B+20.7% | $3.67B+2.8% | $3.57B-9.6% | ||
| $1.99B0.0% | $1.99B0.0% | $1.99B0.0% | $1.99B0.0% | $1.98B0.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $0-100% | $720M0.0% | $720M0.0% | $720M0.0% | $720M0.0% | ||
| $2.13B+5.3% | $2.02B+8.4% | $1.86B+9.4% | $1.7B+1.6% | $1.67B+6.6% | ||
| $9.45B+1.5% | $9.3B+1.0% | $9.21B+11.2% | $8.28B+1.5% | $8.16B-3.0% | ||
| $14.4B+2.9% | $14B+1.5% | $13.79B+2.2% | $13.49B+2.3% | $13.19B+2.6% | ||
| $36.42B+1.8% | $35.8B+2.1% | $35.05B+4.1% | $33.68B+4.0% | $32.38B+2.2% | ||
| $11.9M-84.6% | $77.5M+12.3% | $69M+31.4% | $52.5M+80.4% | $29.1M+468% | ||
| $19.41B+4.3% | $18.61B+3.7% | $17.94B+3.8% | $17.28B+6.6% | $16.22B+6.9% | ||
| $31.42B+0.5% | $31.26B+1.0% | $30.96B+3.4% | $29.94B+1.9% | $29.39B+0.1% | ||
| $40.87B+0.8% | $40.56B+1.0% | $40.17B+5.1% | $38.22B+1.8% | $37.55B-0.6% | ||
| $160.5M-15.6% | $190.2M+12.1% | $169.7M+17.5% | $144.4M+31.3% | $110M-21.3% | ||
| $5.79B+5.5% | $5.49B-7.6% | $5.94B+8.5% | $5.47B+4.1% | $5.26B-19.4% | ||
| $787.9M+8.3% | $727.5M-10.1% | $808.8M+5.8% | $764.4M-1.2% | $773.9M+6.6% | ||
| $571.6M+71.1% | $334M+5.4% | $316.8M0.0% | $316.8M0.0% | $316.8M+98.2% | ||
| $2.13B+16.9% | $1.82B+8.9% | $1.67B+8.9% | $1.54B+10.3% | $1.39B+22.6% | ||
| —— | —— | —— | —— | —— | ||
| $571.6M+71.1% | $334M+5.4% | $316.8M0.0% | $316.8M0.0% | $316.8M+98.2% | ||
| —— | —— | —— | —— | —— | ||
| $571.6M+71.1% | $334M+5.4% | $316.8M0.0% | $316.8M0.0% | $316.8M+98.2% | ||
| $4.19B+2.8% | $4.08B+6.0% | $3.85B+7.7% | $3.57B+3.8% | $3.44B+3.9% | ||
| $1.29B+2.3% | $1.26B-8.9% | $1.38B+2.2% | $1.35B+15.8% | $1.17B+1.6% | ||
| $9.79B-4.6% | $10.26B-0.2% | $10.29B+2.3% | $10.06B+8.4% | $9.28B+4.2% | ||
| $2.13B+16.9% | $1.82B+8.9% | $1.67B+8.9% | $1.54B+10.3% | $1.39B+22.6% | ||
| $5.27B+2.8% | $5.12B+2.4% | $5B+3.3% | $4.84B+3.1% | $4.69B+2.1% | ||
| $2.13B+16.9% | $1.82B+8.9% | $1.67B+8.9% | $1.54B+10.3% | $1.39B+22.6% | ||
| $225.1M+7.9% | $208.7M-4.8% | $219.2M+6.3% | $206.3M-2.6% | $211.8M+14.1% | ||
| $225.1M+7.9% | $208.7M-4.8% | $219.2M+6.3% | $206.3M-2.6% | $211.8M+14.1% | ||
| $2.72B-5.3% | $2.88B-3.3% | $2.98B+20.9% | $2.46B+9.8% | $2.24B-11.3% | ||
| $225.1M+7.9% | $208.7M-4.8% | $219.2M+6.3% | $206.3M-2.6% | $211.8M+14.1% | ||
| $2.71B-9.0% | $2.97B+9.9% | $2.71B0.0% | $2.71B0.0% | $2.7B-8.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | —— | —— | ||
| $15.52B-0.7% | $15.62B+1.2% | $15.43B+10.4% | $13.98B+5.4% | $13.26B-7.5% | ||
| $28.3M+1,032% | $2.5M-58.3% | $6M-41.2% | $10.2M-42.4% | $17.7M-54.6% | ||
| $40.9M-58.5% | $98.5M+5.7% | $93.2M+19.9% | $77.7M+36.3% | $57M+89.4% | ||
| $15.52B-0.7% | $15.62B+1.2% | $15.43B+10.4% | $13.98B+5.4% | $13.26B-7.5% | ||
| $9.64B-5.7% | $10.22B+7.4% | $9.52B+11.0% | $8.57B+6.6% | $8.04B+3.0% | ||
| $5.79B+5.5% | $5.49B-7.6% | $5.94B+8.5% | $5.47B+4.1% | $5.26B-19.4% | ||
| $15.53B-1.2% | $15.71B+1.2% | $15.52B+10.5% | $14.05B+5.6% | $13.3B-7.2% | ||
| $98.4M— | —— | —— | —— | —— | ||
| $571.6M+71.1% | $334M+5.4% | $316.8M0.0% | $316.8M0.0% | $316.8M+98.2% | ||
| —— | —— | —— | —— | —— | ||
| $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | $0.010.0% | ||
| 30M0.0% | 30M0.0% | 30M0.0% | 30M0.0% | 30M0.0% | ||
| 0— | 0— | 0— | 0— | 0— | ||
| 0— | 0— | 0— | 0— | 0— | ||
| —— | —— | —— | —— | —— | ||
| 34.7M+3.0% | 33.7M+3.1% | 32.7M+3.5% | 31.6M+6.4% | 29.7M+5.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Regeneron Pharmaceuticals's total assets?
- Regeneron Pharmaceuticals (REGN) holds $40.9B in total assets, up 8.8% year over year.
- How much debt does Regeneron Pharmaceuticals have?
- Regeneron Pharmaceuticals carries $2.7B in total debt against $31.4B of shareholders' equity, a debt-to-equity ratio of 0.09.
- How much cash does Regeneron Pharmaceuticals have?
- Regeneron Pharmaceuticals holds $3.0B in cash and equivalents.
- Can Regeneron Pharmaceuticals cover its short-term obligations?
- Its current ratio is 3.56 — current assets exceed current liabilities.
- Where does Regeneron Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
